StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the medical technology company’s stock.

Leading industry players, such as BIOLASE, Inc., are at the forefront of this technological transformation. Renowned globally for their pioneering dental laser products, BIOLASE is spearheading market ...